Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 699 | -396 | 0 | 0 | 112 | 77 | 146 |
| Operating profit | CHF m | 587 | 1,350 | |||||
| Net profit | CHF m | 691 | -405 | -358 | -207 | 76 | 578 | 1,349 |
| EPS reported | CHF | 10.54 | 24.50 | |||||
| Operating cashflow per share | CHF | 5.64 | 5.49 | |||||
| Capex per share | CHF | 0.00 | 0.00 | |||||
| FCF per share | CHF | 5.64 | 5.49 | |||||
| Free cash flow | CHF m | 309 | 303 | |||||
| Net debt | CHF m | -99 | -3,076 | |||||
| Book value equity | CHF m | 2,779 | 3,084 | |||||
| Book value per share | CHF | 50.67 | 55.93 | |||||
| Number of shares | m | 54.85 | 55.15 | |||||
| DPS (TTM paid) | CHF | 2.25 | 2.25 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 4.26 | 2.05 | |||||
| P/B LTM | x | 0.89 | 0.90 | |||||
| P/S LTM | x | 32.10 | 19.00 | |||||
| P/FCF LTM | x | 7.97 | 9.16 | |||||
| EV/EBITDA LTM | x | 4.09 | -0.22 | |||||
| EV/Sales LTM | x | 30.82 | -2.07 | |||||
| Earnings Yield LTM | % | 23.47% | 48.78% | |||||
| FCF Yield | % | 12.54% | 10.91% | |||||
| Quality | ||||||||
| ROE | % | 20.81% | 49.95% | |||||
| ROIC | % | 21.06% | 43.70% | |||||
| Operating margin | % | 763.99% | 924.92% | |||||
| Gross margin | % | 99.93% | 100.00% | |||||
| FCF/Sales | % | 402.47% | 207.38% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +663.77% | - | |||||
| Sales Growth YoY | % | -31.19% | - | |||||
| Net Income Growth YoY | % | +661.71% | - | |||||
| FCF Growth | % | +1.51% | -30.51% | |||||
| Operating Profit Growth | % | +595.29% | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 3.99% | 4.47% | |||||
| Dividend Growth | % | +25.00% | +25.00% | |||||
| Payout Ratio | % | 17.04% | 9.20% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -0.17 | -0.15 | |||||
| EBIT/Net interest | x | 1,324.68 | 0.00 | |||||
| Net debt/market cap | % | -4.03% | -110.90% | |||||
| Net debt/Equity | x | -0.04 | -1.00 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free